Summary
This paper presents clinical best-practice recommendations for managing adverse events in patients receiving the combination therapy of enfortumab vedotin (an antibody-drug conjugate targeting Nectin-4) and pembrolizumab (an immune checkpoint inhibitor) for locally advanced or metastatic urothelial cancer. The recommendations address four key adverse events—skin reactions, peripheral neuropathy, hyperglycemia, and pneumonitis—which may arise from either agent individually, complicating clinical attribution and management. The guidance synthesises published clinical guidelines, expert opinion, and author clinical experience to support optimal patient care with this FDA-approved combination regimen.
UK applicability
The recommendations are likely applicable to UK oncology practice, as urothelial cancer treatment protocols are broadly aligned internationally and FDA-approved therapies typically undergo similar evaluation in the United Kingdom. However, NHS formulary status and reimbursement decisions may affect implementation in UK clinical settings.
Key measures
Adverse event management protocols and best-practice recommendations for skin reactions, peripheral neuropathy, hyperglycemia, and pneumonitis
Outcomes reported
The study reports clinical recommendations for managing adverse events associated with the combination therapy of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer. Specific adverse events addressed include skin reactions, peripheral neuropathy, hyperglycemia, and pneumonitis.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.